Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Фаза 1/2 Завершено NCT03410030

Заболевание	Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma
Фаза	Фаза 1/2
Спонсор	HonorHealth Research Institute
Статус	Завершено
Участники	17 участн.
Вмешательство	High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2
Дата начала	15.12.2017
Дата завершения	14.09.2021
Публикация результатов	23.07.2026

Кратко

The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.

Total Dose Received [Identifying Recommended Maximum Tolerated Dose (MTD)]

From enrollment through end of treatment, up to 40 weeks · Dose (g/m^2)

Ascorbic Acid 25 g/m^2	235.3 ± 66.3 Dose (g/m^2)
Ascorbic Acid 37.5 g/m^2	410.4 ± 62.0 Dose (g/m^2)
Ascorbic Acid 56.25 g/m^2	589.1 ± 135.7 Dose (g/m^2)

Duration of Dose in Days [Identifying Recommended Maximum Tolerated Dose (MTD)]

From enrollment through end of treatment, up to 40 weeks · Days

Ascorbic Acid 25 g/m^2	235.5 ± 51.9 Days
Ascorbic Acid 37.5 g/m^2	165.9 ± 51.4 Days
Ascorbic Acid 56.25 g/m^2	149.0 ± 54.2 Days

Duration of Dose in Weeks [Identifying Recommended Maximum Tolerated Dose (MTD)]

From enrollment through end of treatment, up to 40 weeks · Weeks

Ascorbic Acid 25 g/m^2	33.6 ± 7.4 Weeks
Ascorbic Acid 37.5 g/m^2	23.7 ± 7.3 Weeks
Ascorbic Acid 56.25 g/m^2	21.3 ± 7.7 Weeks

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroqu — Massachusetts General Hospital
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский